Prevention and management of adverse events related to regorafenib.

Support Care Cancer · 2014 · PMC3913844 · PMID 24337717

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Because of the high rate of crossover (85 % of the placebo group crossed over on disease progression to receive open-label regorafenib), the overall survival results from GRID did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.